BELLONE, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 1.863
AS - Asia 695
EU - Europa 426
SA - Sud America 143
Continente sconosciuto - Info sul continente non disponibili 46
AF - Africa 11
OC - Oceania 2
AN - Antartide 1
Totale 3.187
Nazione #
US - Stati Uniti d'America 1.807
CN - Cina 234
SG - Singapore 232
UA - Ucraina 117
BR - Brasile 113
HK - Hong Kong 71
IT - Italia 67
DE - Germania 55
FI - Finlandia 52
VN - Vietnam 52
CA - Canada 37
FR - Francia 29
IN - India 24
TR - Turchia 24
GB - Regno Unito 23
IE - Irlanda 18
RU - Federazione Russa 17
BD - Bangladesh 16
AR - Argentina 13
MX - Messico 8
ID - Indonesia 7
NL - Olanda 7
PL - Polonia 7
EC - Ecuador 6
SE - Svezia 6
JP - Giappone 5
ES - Italia 4
IQ - Iraq 4
LT - Lituania 4
SA - Arabia Saudita 4
ZA - Sudafrica 4
AT - Austria 3
BE - Belgio 3
CO - Colombia 3
CZ - Repubblica Ceca 3
KG - Kirghizistan 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
AZ - Azerbaigian 2
BY - Bielorussia 2
CR - Costa Rica 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MA - Marocco 2
MY - Malesia 2
PK - Pakistan 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AQ - Antartide 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
BZ - Belize 1
CL - Cile 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
LK - Sri Lanka 1
LY - Libia 1
MK - Macedonia 1
PE - Perù 1
PS - Palestinian Territory 1
RO - Romania 1
SX - ???statistics.table.value.countryCode.SX??? 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 3.142
Città #
Fairfield 180
Ashburn 161
Woodbridge 158
Singapore 134
Houston 114
Jacksonville 76
Wilmington 72
Hong Kong 70
Ann Arbor 68
Seattle 68
San Jose 67
Cambridge 62
New York 62
Beijing 47
Dearborn 43
Council Bluffs 42
Nanjing 34
Helsinki 33
Los Angeles 33
Chandler 32
Princeton 30
Indianapolis 27
The Dalles 25
Ho Chi Minh City 20
Istanbul 18
Dublin 17
Lauterbourg 16
Orem 16
Chicago 15
Shanghai 15
Toronto 14
Hanoi 13
San Francisco 13
Santa Clara 13
São Paulo 13
Columbus 11
Denver 11
Moscow 11
Shenyang 11
Des Moines 10
Munich 10
North Bergen 10
Montreal 9
Chennai 8
Dallas 8
Milan 8
Nanchang 8
San Diego 8
Atlanta 7
Kunming 7
Redondo Beach 7
Rome 7
Belo Horizonte 6
Buffalo 6
Charlotte 6
Mooresville 6
Warsaw 6
Amsterdam 5
Brescia 5
Brooklyn 5
Hebei 5
Jiaxing 5
Jinan 5
Ningbo 5
Paris 5
Tianjin 5
Tokyo 5
Boston 4
Da Nang 4
London 4
Mumbai 4
Nuremberg 4
Stockholm 4
Turku 4
Arezzo 3
Bishkek 3
Brasília 3
Brussels 3
Changsha 3
Guangzhou 3
Guarulhos 3
Hangzhou 3
Hefei 3
Kilburn 3
Monmouth Junction 3
Pelotas 3
Phoenix 3
Querétaro 3
Amman 2
Auburn Hills 2
Baghdad 2
Baku 2
Bismarck 2
Biên Hòa 2
Boardman 2
Catanduva 2
Chaguanas 2
Chongqing 2
City of London 2
Dammam 2
Totale 2.146
Nome #
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor 245
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 220
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 212
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. 199
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas 198
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 197
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 174
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 174
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody 174
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab. 173
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor 166
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcomas cell lines is linked to tubulin-beta-III expression. 162
Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2) 157
Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody 151
Serum amyloid A: a novel biomarker for endometrial cancer. 131
Integrated mutational landscape analysis of uterine leiomyosarcomas 130
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 114
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 109
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 99
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. 2
Totale 3.187
Categoria #
all - tutte 13.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.566


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202295 0 0 0 0 1 11 11 6 4 22 14 26
2022/2023138 22 3 3 6 13 27 5 16 18 0 13 12
2023/2024173 13 11 20 4 8 38 13 5 33 6 1 21
2024/2025307 1 4 2 37 22 37 20 7 38 23 76 40
2025/2026958 94 93 74 199 120 59 155 21 44 59 26 14
2026/2027226 34 34 52 94 12 0 0 0 0 0 0 0
Totale 3.187